Azacitidine plus rotercept for higher-risk MDS
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of two drugs, azacitidine and rotercept, for people with a type of blood cancer called myelodysplastic syndrome (MDS) that has a higher risk of progressing. The goal is to see if adding rotercept helps control the disease better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with higher-risk MDS (a blood disorder).
- You have not yet received treatment for your MDS.
- Your liver and kidney function are within normal limits.
- You are physically able to care for yourself (ECOG score 2 or less) and expected to live at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called lisaftoclax combined with a standard treatment, azacytidine, for people newly diagnosed with higher-risk myelodysplastic syndrome (MDS). The goal is to see if the combination helps control the disease better than what's currently available.
This Phase 2 study tests whether combining azacitidine and ruxolitinib can better control higher-risk bone marrow diseases (MDS/MPN, including CMML). It may help patients who are not good candidates for a stem cell transplant and who can safely take these medicines.
This Phase 3 trial tests whether doing an “allogeneic” stem cell transplant works best for people newly diagnosed with higher-risk MDS (a bone marrow disorder). It’s mainly for patients who are healthy enough to receive a transplant and haven’t started MDS treatment yet.
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
This trial tests whether adding bexmarilimab to standard azacitidine treatment helps people with higher-risk myelodysplastic syndromes (MDS), a type of blood cancer. It compares this combination to azacitidine plus a placebo to see which is more effective.
This trial tests a new drug, AK117, combined with azacitidine for people newly diagnosed with high-risk myelodysplastic syndromes (MDS), a blood disorder. The goal is to see if the combination can help improve outcomes.
Hear when a new Higher-risk Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.